Navigation Links
Sinapis Pharma Closes Series 'A' Financing
Date:11/17/2009

JACKSONVILLE, Fla., Nov. 17 /PRNewswire/ -- Sinapis Pharma, Inc. has successfully completed a Series "A" Preferred stock offering that has raised $510,000 for its ongoing drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.

The current financing will allow the company to reach significant development milestones. Investigational New Drug (IND) application submission to the FDA is anticipated for December 2009 with a Phase I clinical trial commencing in the first quarter of 2010. A Phase II proof of concept study is expected to commence in late 2010 for the stroke indication in humans.

Dr. Donald Picker, Sinapis CEO, relates: "We are excited that we can begin the development of methamphetamine for stroke. We have a rapid, inexpensive development pathway to proof of principle in man within 24 months due to the drug's previous human use for other indications, and anticipate being the first drug to enter stroke clinical trials with solid 6-12 hour pre-clinical data."

Sinapis Pharma, Inc. (www.sinapispharma.com) is an early stage biotechnology company whose lead compound methamphetamine, as a low-dose intravenous infusion, has shown remarkable pre-clinical efficacy in stroke and brain injury models.

For more information contact Dr. Picker at Don.Picker@gmail.com.

SOURCE Sinapis Pharma, Inc.


'/>"/>
SOURCE Sinapis Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... , April 19, 2017 Global Prostate ... report on the prostate cancer therapeutics market analyzes ... market. Increasing prevalence of prostate cancer, launch of ... the development of new drugs & therapeutic biological ... drug due to lesser side effects are some ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join ... This festival offers entertainment for everyone — from the avid gardener to the landscape ... very high quality event held in a grand venue, and we are certainly looking ...
(Date:4/21/2017)... ... April 21, 2017 , ... A new medical study ... replacement patients; post-operative recovery just might be even better than they imagined. Researchers ... osteoarthritis following surgery: 262 patients under 65 and 103 patients over 75. The ...
(Date:4/21/2017)... ... April 21, 2017 , ... National pest management association survey conducted in 2010 ... bug infestations over the 5-year period. In 2015 10% or US$750 million per annum ... bug infested properties. , The health and economic consequences of bed bug ...
(Date:4/21/2017)... ... April 21, 2017 , ... In a recently released ... a summer camp for kids in Dana Point, parents are challenged to find ways ... writers caution parents to find age appropriate activities that both reinforce their child’s learning ...
(Date:4/20/2017)... Carolina (PRWEB) , ... April 20, 2017 , ... ... of the fourth book in its growing library. The Greener The Grass, ... Quarterback and alumnus of Walnut Grove High School, shares a deeply personal, hard-earned ...
Breaking Medicine News(10 mins):